> More cholesterol-lowering drugs are being prescribed as generic formulas of the drugs hit the market. Release
> Elixir Pharmaceuticals and Siena Biotech have entered into an agreement to collaborate on the optimization, validation and evaluation of Elixir's SIRT1 inhibitors in Huntington's disease. Release
> Generic drugmaker Actavis Group acquired a division of India-based Sanmar Specialty Chemicals. Activis hopes the acquisition will reduce manufacturing costs. Report
> PE firm Avista Capital Partners said it will acquire BioReliance Corporation, a business unit of Invitrogen Corporation $210 million. Release
And Finally... Denmark's biotech industry is heating up. Report (WSJ sub. req.)